Press Release | Bentham Science announces new multidisciplinary journal, ‘Current Chinese Science’





Bentham Science announces an important new multidisciplinary journal, Current Chinese Science. This will be the world’s largest journal with over 4,000 leading Chinese scientists involved on its editorial board.

Current Chinese Science is a peer reviewed journal with over 70 sections headed by leading Chinese scientists as Co-Editors. The journal will cover important and emerging fields in agriculture, science, engineering, medicine and other areas. The journal aims to provide researchers and scholars a strong platform to publish their work and share their findings with readers around the world. The Honorary Editors of the journal are Prof. Ferid Murad (Nobel Laureate) and Prof. Atta-Ur-Rahman, FRS (Academician Chinese Academy of Sciences, and UNESCO Science Laureate).

The journal will be essential reading for scientists and scholars involved in a variety of scientific disciplines, largely reflecting the tremendous scientific progress being made in China. Every article in the first issue of Current Chinese Science will be published as Open Access (Free-to-download) for a limited time period of three months. Visit the journal website for further details:



Read full Press Release to find out more:

Animated Abstract | Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps

Extend the scope and visibility of your research by creating an animated abstract.


Bentham Science has collaborated with Focus Medica, one of the world’s largest publishers of expert animated atlases and videos in medicine and science.

An animated abstract will help summarise the essential discoveries/ key findings of your published research or review article. Each professionally produced full-coloured animated abstract in video format (length 3 – 5 minutes) is accompanied by an English spoken or foreign language commentary. The animated abstract will be published online along with the published article.

The payment for an animated abstract will be US$ 1400 for English language, and US$ 1900 for Foreign language articles. Initially, an advance payment of US$ 500 of the total payment will be payable to the Publisher to start work on the Animated Abstract, US$ 900 (English language) or US$ 1400 (Foreign language) will be payable on completion of the Animated Abstract.

Authors who opt for the “Animated Abstract” option and also wish to have their article made available on an “Open Access Plus” basis will be entitled to a 50% discount only on the Animated Abstract fee and, in addition, pay the normal Open Access Plus fee.

Authors will be asked whether they wish to opt-in for this paid service, and if not, the article will be published as normal. Animated abstracts are available as open access (free viewing) for maximum visibility and awareness to your readers at anytime, anywhere. The animated abstracts are licensed under the terms of the Creative Commons Attribution – NonCommercial-NoDerivatives 4.0 International Public License (CC BY-NC-ND 4.0)

One of our animated abstracts can be viewed below:

Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps

Journal Name: Current Medicinal Chemistry

Author(s): Hannah Y. Mahmood, Shirin Jamshidi, J. Mark Sutton, Khondaker M. Rahman.




Antimicrobial resistance represents a significant challenge to future healthcare provision.An acronym ESKAPEE has been derived from the names of the organisms recognised as the major threats although there are a number of other organisms, notably Neisseria gonorrhoeae, that have become equally challenging to treat in the clinic. These pathogens are characterised by the ability to rapidly develop and/or acquire resistance mechanisms in response to exposure to different antimicrobial agents. A key part of the armoury of these pathogens is a series of efflux pumps, which effectively exclude or reduce the intracellular concentration of a large number of antibiotics, making the pathogens significantly more resistant. These efflux pumps are the topic of considerable interest, both from the perspective of basic understanding of efflux pump function, and its role in drug resistance but also as targets for the development of novel adjunct therapies. The necessity to overcome antimicrobial resistance has encouraged investigations into the characterisation of resistance-modifying efflux pump inhibitors to block the mechanisms of drug extrusion, thereby restoring antibacterial susceptibility and returning existing antibiotics into the clinic. A greater understanding of drug recognition and transport by multidrug efflux pumps is needed to develop clinically useful inhibitors, given the breadth of molecules that can be effluxed by these systems. This review discusses different bacterial EPIs originating from both natural source and chemical synthesis and examines the challenges to designing successful EPIs that can be useful against multidrug resistant bacteria. To know more about our Animated Abstract, please visit:

New Issue | Current Nanoscience; Volume 16 Issue 1



Current Nanoscience publishes (a) Authoritative/Mini Reviews, and (b) Original Research and Highlights written by experts covering the most recent advances in nanoscience and nanotechnology. All aspects of the field are represented including nano-structures, nano-bubbles, nano-droplets and nanofluids. Applications of nanoscience in physics, material science, chemistry, synthesis, environmental science, electronics, biomedical nanotechnology, biomedical engineering, biotechnology, medicine and pharmaceuticals are also covered. The journal is essential to all researches involved in nanoscience and its applied and fundamental areas of science, chemistry, physics, material science, engineering and medicine.

Current Nanoscience also welcomes submissions on the following topics of Nanoscience and Nanotechnology:

  • Nanoelectronics and photonics
  • Advanced Nanomaterials
  • Nanofabrication and measurement
  • Nanobiotechnology and nanomedicine
  • Nanotechnology for energy
  • Sensors and actuator
  • Computational nanoscience and technology

Articles from the journal: Current Nanoscience; Volume 16 Issue 1




For details on the articles, please visit this link:

Aims and Scope | Current Bioinformatics

Current Bioinformatics aims to publish all the latest and outstanding developments in bioinformatics. Each issue contains a series of timely, in-depth/mini-reviews, research papers and guest edited thematic issues written by leaders in the field, covering a wide range of the integration of biology with computer and information science.

The journal focuses on advances in computational molecular/structural biology, encompassing areas such as computing in biomedicine and genomics, computational proteomics and systems biology, and metabolic pathway engineering. Developments in these fields have direct implications on key issues related to health care, medicine, genetic disorders, development of agricultural products, renewable energy, environmental protection, etc.

Current Bioinformatics is an essential journal for all academic and industrial researchers who want expert knowledge on all major advances in bioinformatics. To know more about the journal, please visit:



Bentham Science: How We Avoid Predatory Publishing


Bentham Science Publishers publishes over 140 scholarly journals (Subscription based and Open Access) related to various subject areas of science, technology and medicine. The journals are indexed, recognized and associated with reputable scientific agencies, directories and other entities.

Each article submitted to Bentham Science journals (Subscription and Open Access) is rigorously peer-reviewed. You can read more about our peer review process here. Bentham’s publications are also part of COPE, an organization that aims to define best practice in the ethics of scholarly publishing and to assist authors, editors and publishers to achieve the defined standards. We have several notable journals included in the Journal Citation Reports of Clarivate Analytics with Impact Factor rankings.

The article published in Springer, Medicine, Health Care and Philosophy, that discusses predatory publishing, highlighted a link from a controversial list by Jeffery Beall which has been taken down due to its controversial nature. However, even if one considers his list, he had included publishers such as Biomed Central (part of the Springer-Nature group), Frontier Science etc., all of which are thoroughly respected and reputable publishers. This does not mean that those 2 publishers are predatory, and the same rule applies here. Bentham Science has promptly and clearly addressed all allegations in the past, of any predatory practices, and has duly satisfied its stakeholders and maintained their trust and association. Repetition of such claims is false and misleading. To read the full blog, please visit:


4th Microbiome R&D and Business Collaboration Forum: Europe


Global Engage is pleased to announce the 4th Microbiome R&D and Business Collaboration Forum: Europe which will be held on 3-4 April 2017.

For more details visit:

4th Microbiome R&D and Business Collaboration Forum: Europe


Global Engage is pleased to announce the 4th Microbiome R&D and Business Collaboration Forum: Europe which will be held on 3-4 April 2017.

For more details visit:

eBooks Catalog – Medicine

Catalog Description:

This catalogue of our eBook titles in medicine comprises various ebooks on advances in Alzheimer research, antibodies applications and new developments, advances in anti-cancer agents in
medicinal chemistry, angiogenesis and therapeutic targets in cancer, cardiac resynchronization therapy, chemical induced seizures, chemoinformatics, bioencapsulation of living cells for diverse medical applications, dermatological treatments, electrocardiography, glucose homeostatis and insulin resistance, immunology of pregnancy, kidney transplantation, tuberculosis treatment, helicobacter pylori, therapeutic revolution, surgical inflammation, thyroid cancer, stem cell and regenerative medicine, oral infections and cardiovascular disease, physiologic autoimmunity and preventive medicine and many more.
Download here.


Maximising the Value of Imaging in Oncology Drug Development, 12-13 March, London, UK

Maximising the Value of Imaging in Oncology Drug Development, 12-13 March, London, UK

The roll of medical imaging is and will continue to be vital. This must attend event will feature a line-up of leading experts including Novartis, GSK, Roche, Cancer Research UK, TNO and more, providing attendees with insight into the industry and its future.

For more information, please contact Daniel Lee at

Scientists home in on ‘good’ gut germs for weight loss, health

Researchers say they are homing in on the particular gut microbes that can make you fat, or keep you free of irritable bowel disease. Their goal? Maybe infusions of good, clean germs to treat disease.


They found a set of bacteria that seem to help control how much fat the body layers on, and a separate set that affect the immune system. And they think they’ve got a system for testing which bacteria, out of hundreds of species living in the gut, might be important for health.

“We can culture these organisms, manufacture these organisms in pure form … so they could be administered to individuals in the future,” says Dr. Jeffrey Gordon of Washington University in St. Louis, who led the research team.

“We could generate a 21st-century medicine cabinet ,” he added.

Writing in the journal Science Translational Medicine, the researcher said they used specially bred sterile mice and poop donations from five healthy adults to identify particular species of bacteria that regulate helpful immune system cells called regulatory T-cells, and that helped mice put on a layer of body fat.

Every human carries pounds of microorganisms on our skin and in our guts that we couldn’t live without. They break down food, prevent infections and extract nutrients like vitamin K. Scientists believe at least 10,000 different species live in and on us, with hundreds of species and trillion of individual bacteria in our digestive systems.

Some studies also show they may affect our weight, by helping convert food to fat or by passing it along quickly before the body absorbs too many calories. They also may affect diseases such as Crohn’s disease and irritable bowel syndrome by altering the balance of regulatory T-cells.

Fecal transplants can help beef up a patient’s gut microbiome and cure a deadly diarrheal infection called Clostridium difficile, which kills more than 14,000 people in the United States every year. They can affect metabolism, and Gordon’s team has already shown that bacteria from obese humans made mice pack on fat

“We developed a new way of sorting through populations and identifying the responsible organiams, the key actors,” Gordon said in a telephone interview.

In one experiment, the team identified eight different species of bacteria from lean, healthy women that made the mice put on fat. “We started out with a sterile mouse,” Gordon said. They knew germ-free mice are always skinnier than mice with a normal load of gut bacteria.

It’s hard to tell if the mice actually put on weight – they were growing anyway – but they put on a clear layer of fat after getting the purified human bacteria, even as they ate exactly the same food as other mice that didn’t get the bacteria and that stayed lean.

The bacteria that help mice gain weight includes species called Bacteroides intestinalis, B. ovatus, B. vulgatus, B. caccae, and B. thetaiotaomicron.

The team also identified a species of bacteroides that seemed to help the mice produce more regulatory T cells – something that in people should help protect against inflammatory diseases such as Crohn’s disease, irritable bowel syndrome and perhaps even some effects of diabetes.

Gordon’s team had earlier shown that people appear to have their own unique populations of bacteria, and that they pretty much keep the same distribution through life.

But they and others have also shown it’s possible to change the makeup, at least a little, through diet. “We know that diet is a huge driver in the activity of the gut community,” Gordon said.

So if scientists can identify the best bacteria for keeping people lean and healthy, they can at least diagnose illness by testing for those species, and perhaps find ways to change the balance.

“There is not a single magic organism that has the power the regulate the body,” Gordon cautions. It’s more likely to be a combination that works. In the meantime, while fecal transplants are definitely shown to cure C. difficile infections , Gordon does not recommend clinics that claim to treat weight loss with poop transplants from slim people.


%d bloggers like this: